Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 18Kidney Neoplasms 2Urogenital Neoplasms 1Thrombocytopenia 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Genital Neoplasms, Male 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Anemia 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1epacadostat 1angiotensin I (1-7) 1Pluvicto 1Peripheral Blood Stem Cell Transplantation 1Metformin 1IDO-1 inhibitor LY3381916 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Emapalumab 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cytopenia × Pluvicto × Clear all
NCT07025512 2026-05-08

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Classical hematology

Cytopenia, Anemia, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡